Recently, Suzhou RainMed Medical Technology Co., Ltd. frequently obtained the recognition of industry authority , showing its excellent comprehensive strength and leading advantage in research and development level and innovation as well as business layout.

In the 4th GuruClub Greater China Best Listed Company Awards 2022 published by GuruClub, the most significant investment research platform in China, RainMed Medical won the Annual Innovation Award.

The award covers all Chinese companies listed in Hong Kong Stock Exchange, Shanghai Stock Exchange and Shenzhen Stock Exchange, as well as those listed in the United States, and has got extensive attention of the enterprises and capital market. As a dark horse listed in Hong Kong stock market, RainMed Medical stands out among many listed enterprises, which indicates that it has been widely recognized by the top investment platform in the industry due to its excellent product innovation, effective marketing capability, and perfect software and hardware strength.

RainMed also won the Most Valuable Pharmaceutical and Medical Company Award among more than 1,000 listed companies listed in the Hong Kong Stock Exchange and in the United States in the 7th Annual list of Listed Companies hosted by Zhitong Financial and Tonghuashun Financial, the leading domestic stock information platforms.

The awards are designed to recognize Hong Kong-US listed pharmaceutical and medical companies with good governance structures, prominent industry positions, well-run main businesses and consistent returns of value to investors. In this selection, RainMed Medical fully demonstrated to the expert committee its rapid performance growth, excellent governance ability, high-quality marketing level, strong market growth potential, and extensive public satisfaction in the past year.

Founded in 2014, RainMed Medical is committed to becoming world's leading vascular interventional surgical robot company. At present, it has caFFR system, coronary functional measurement system with the highest accuracy in China; caIMR system, the only non-interventional coronary microcirculation measurement product in the world; and FlashBot, the first vascular interventional surgery robot covering the whole process of diagnosis and treatment in China; It aims to develop RDN system to assist the robot system to achieve accurate diagnosis and treatment of refractory hypertension.